<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T04:13:44Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/27873" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/27873</identifier><datestamp>2026-09-24T00:36:25Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Ask, Kjetil</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Revill, Spencer</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Medical Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2022-09-26T21:18:07Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2022-09-26T21:18:07Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2022-11</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/27873</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/23468</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Histological and visual assessment of pulmonary fibrosis are used as a &#xd;
gold standard to determine severity of fibrotic lung disease. The Ashcroft scoring &#xd;
technique and histological stains like Masson’s trichrome and picrosirius red &#xd;
(PSR) have been used for decades as primary readouts, often alongside a &#xd;
biochemical assay estimating the amount of hydroxyproline in the tissue. As &#xd;
pulmonary fibrosis is a heterogeneous disease and collagen content rarely shows &#xd;
more than a two-fold increase between a non-diseased and a diseased lung, &#xd;
therapeutic assessment is challenging due to the variability animal models. &#xd;
 To improve the assessment of the severity of fibrotic lung disease, we &#xd;
have developed models using multivariate linear regression and XGBoost &#xd;
machine learning that consider digital quantifications of histological features from &#xd;
73 clinically diagnosed cases of IPF and 11 control tissues, obtained using the &#xd;
HALO® platform, that correlate with the Ashcroft score and combine them into a &#xd;
composite index that we believe represents a better, more objective way of &#xd;
scoring fibrotic lung tissues. &#xd;
The tissues were stained with H&amp;E for structural assessment, Trichrome &#xd;
(TRI), and Picrosirius Red (PSR) for collagen content, alpha-smooth muscle actin &#xd;
(αSMA) to assess the amount of ECM-producing myofibroblasts (MFBs), and &#xd;
CD68, CD163, and CD206 for macrophage content and activation as they have &#xd;
been correlated with lung fibrosis and are considered a therapeutic target.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="layabstract" lang="en_US">Lung diseases involving excess scar tissue formation resulting in lung &#xd;
failure are difficult to study, especially when the most used method for assessing &#xd;
the progression of the disease, the Ashcroft score, is imprecise and subject to &#xd;
bias. The goal with this project is to update this current gold standard for rating &#xd;
disease severity in a portion of lung from the purely visual Ashcroft score to one &#xd;
that uses robust computational methods.  &#xd;
This novel method uses digital pathology software, HALO®, to quantify &#xd;
components of the lung tissue, such as population densities of specific cell types, &#xd;
the proportion of alveolar airspace to alveolar interstitium, and the extent of &#xd;
scarring in the lung according to collagen content. Then, machine learning is &#xd;
used to generate a severity score that resembles the standard method, and &#xd;
should feel familiar to lung researchers, but that we believe is more reliable and &#xd;
would be consistent between research groups.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Fibrosis, Lung, Histology, Digital Pathology, HALO®, Composite Index, Model, Machine Learning</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">DEVELOPING A HISTOLOGY-BASED COMPOSITE INDEX TO ASSESS THE  DEGREE OF LUNG FIBROSIS USING QUANTITATIVE HALO® MODULES</dim:field>
   <dim:field mdschema="dc" element="title" qualifier="alternative" lang="en_US">USING QUANTITATIVE HISTOLOGICAL READOUTS OF PULMONARY  FIBROSIS TO PRODUCE A SCORE OF FIBROTIC LUNG DISEASE SEVERITY</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>